Guggenheim Raises AbbVie Price Target to $322 From $288
Guggenheim adjusted its price target on AbbVie to $322 from $288.
Related stories
Oracle Shares Fall After Announcing Stock and Bond Transactions
Oracle announced stock transactions and bond transactions; its shares fell.
L impact | EQUITY | Nov 02, 2026, 01:56 PM UTC
Fox Reports Higher Q1 FY27 EPS and Revenue
Fox reported year-over-year increases in Q1 FY27 earnings per share and revenue.
M impact | EQUITY | Nov 02, 2026, 01:47 PM UTC
IDEXX Executive Says Covet Revenue Run Rate Is About $20 Million
An IDEXX executive said Covet revenue is growing at strong double-digit rates.
M impact | EQUITY | Nov 02, 2026, 01:46 PM UTC
Infineon and Qualcomm Technologies Sign Automated Driving Agreement
M impact | EQUITY | Nov 02, 2026, 01:46 PM UTC
Fox Shares Rise After Q1 Results Top Estimates
Fox shares rise after first-quarter results top estimates, supported by advertising.
M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC
AAR Proposes $955 Million and $960 Million Senior Note Offerings
AAR proposed $955 million of senior notes due 2031 and $960 million of senior notes due 2034.
M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC